Adi Cohen
Columbia University · Orbix medical
Built from public records under this name as ClinicalTrials.gov spells it. A name can belong to more than one person, so each section says how its rows were tied to this name. No contact details are shown.
Trials
Studies that name Adi Cohen as principal investigator, study chair or study director, newest first. Live from ClinicalTrials.gov, fetched 2026-11-12 01:46 UTC. Open this list on ClinicalTrials.gov
- Ph2NCT04800367 · Romosozumab/Denosumab Study for Premenopausal IOPColumbia University · active not recruiting · Premenopausal Idiopathic Osteoporosis · principal investigator
- Ph2NCT02049866 · Denosumab for Prevention of Post-Teriparatide Bone Loss in Premenopausal Women With IOPElizabeth Shane · completed · Adult Idiopathic Generalized Osteoporosis · principal investigator
- Ph2NCT01440803 · Forteo Trial on Idiopathic Osteoporosis in Premenopausal WomenElizabeth Shane · completed · Adult Idiopathic Generalized Osteoporosis · study director
- N/ANCT00774059 · Evaluation of Safety and Performance of the Orbix Breast Lift SystemMaastricht University Medical Center · withdrawn · Breast Ptosis · study director
- Ph2/Ph3NCT00697463 · Forteo for the Treatment of Unexplained Osteoporosis in Premenopausal WomenColumbia University · completed · Menopause, Fracture, Osteoporosis · study director
Grants
NIH projects from RePORTER, fetched 2026-11-12 01:46 UTC. A project is listed only when its grant number is on one of the trials above, or when the awardee institution matches an affiliation the registry gives for this name. Coverage is US federal funding only; UK and EU funders are not searched yet.
- Pregnancy and lactation associated osteoporosis: Bone microstructure and metabolism, genotypic characteristics, natural history and biomarkers of disease severityR01FD006007 · FDA · COLUMBIA UNIVERSITY HEALTH SCIENCES · fiscal years 2017 to 2021 · $393,866 awarded in 2021Same name and institution; not confirmed by an ID
- Teriparatide for Idiopathic Osteoporosis in Premenopausal Women: A Phase 2 StudyR01FD003902 · FDA · COLUMBIA UNIVERSITY HEALTH SCIENCES · fiscal years 2017 to 2019 · $499,998 awarded in 2019Same name and institution; not confirmed by an ID
- IGF-1, bone turnover and response to teriparatide in premenopausal women with IOPR03AR064016 · NIAMS · COLUMBIA UNIVERSITY HEALTH SCIENCES · fiscal years 2013 to 2015 · $80,000 awarded in 2015Same name and institution; not confirmed by an ID
- Bone Quality in Premenopausal Women with Idiopathic Fragility FracturesK23AR054127 · NIAMS · COLUMBIA UNIVERSITY HEALTH SCIENCES · fiscal years 2007 to 2011 · $128,386 awarded in 2011Same name and institution; not confirmed by an ID
Most cited trial papers
Clinical-trial papers with this author name, ranked by citations from NIH iCite, fetched 2026-11-12 01:46 UTC. The ranking covers the 200 most relevant of 728 PubMed records, and a shared surname and initials can bring in a namesake. All 728 on PubMed
- Oral rivaroxaban for symptomatic venous thromboembolism.N Engl J Med · 20102,485 citationsRCR 79.2
- Oral rivaroxaban for the treatment of symptomatic pulmonary embolism.N Engl J Med · 20121,815 citationsRCR 65.2
- Oral apixaban for the treatment of acute venous thromboembolism.N Engl J Med · 20131,781 citationsRCR 65.1
- Prophylaxis versus episodic treatment to prevent joint disease in boys with severe hemophilia.N Engl J Med · 20071,584 citationsRCR 46.7
- 1,261 citationsRCR 37.4
- 1,171 citationsRCR 43.0
- Apixaban for extended treatment of venous thromboembolism.N Engl J Med · 20131,027 citationsRCR 37.1
- Duration of prophylaxis against venous thromboembolism with enoxaparin after surgery for cancer.N Engl J Med · 2002838 citationsRCR 23.4
- Apixaban for the Treatment of Venous Thromboembolism Associated with Cancer.N Engl J Med · 2020812 citationsRCR 44.9
- Hepatic arterial infusion of chemotherapy after resection of hepatic metastases from colorectal cancer.N Engl J Med · 1999731 citationsRCR 20.1